Clinical Trial Detail

NCT ID NCT02652455
Title Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Nivolumab

Aldesleukin + Cyclophosphamide + Fludarabine

Urelumab

Age Groups: adult

No variant requirements are available.